NRX Pharmaceuticals, Inc. SEC filings NRXP
NRX Pharmaceuticals, Inc. has 477 filings in SEC EDGAR's recent list, going back to Oct 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | May 22, 2026 | — |
| EFFECT | Filing | Dec 22, 2025 | — |
| CORRESP | Letter to the SEC | Dec 18, 2025 | — |
| NT 10-Q | Form nt 10-q | Aug 14, 2025 | Jun 30, 2025 |
| RW | Form rw | Jun 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2025 | — |
| D | Filing | Mar 7, 2025 | — |
| EFFECT | Filing | Jun 21, 2022 | — |
| CORRESP | Letter to the SEC | Jun 16, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2022 | — |
| EFFECT | Filing | Jun 10, 2022 | — |
| EFFECT | Filing | May 3, 2022 | — |
| EFFECT | Filing | May 3, 2022 | — |
| EFFECT | Filing | Apr 19, 2022 | — |
| CORRESP | Letter to the SEC | Apr 18, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2022 | — |
| POS EX | Filing | Apr 8, 2022 | — |
| POS EX | Filing | Apr 8, 2022 | — |
| EFFECT | Filing | Sep 15, 2021 | — |
| CORRESP | Letter to the SEC | Sep 13, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2021 | — |
| EFFECT | Filing | Jul 9, 2021 | — |
| CORRESP | Letter to the SEC | Jul 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2021 | — |
| SEC STAFF LETTER | Filing | May 26, 2021 | — |
| 25-NSE | Delisting notice | May 24, 2021 | — |
| 25-NSE | Delisting notice | May 24, 2021 | — |
| EFFECT | Filing | May 21, 2021 | — |
| CORRESP | Letter to the SEC | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | May 21, 2021 | — |
| CORRESP | Letter to the SEC | May 21, 2021 | — |
| CORRESP | Letter to the SEC | May 20, 2021 | — |
| UPLOAD | Letter from the SEC | May 19, 2021 | — |
| NT 10-Q | Primary document | May 14, 2021 | Mar 31, 2021 |
| 425 | Filing | May 14, 2021 | — |
| CORRESP | Letter to the SEC | May 11, 2021 | — |
| UPLOAD | Letter from the SEC | May 5, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 21, 2021 | — |
| 425 | Filing | Apr 19, 2021 | — |
| CORRESP | Letter to the SEC | Apr 16, 2021 | — |
| NT 10-K | Filing | Apr 1, 2021 | Dec 31, 2020 |
| 425 | Form 425 | Mar 29, 2021 | — |
| 425 | Current report | Mar 22, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2021 | — |
| 425 | Current report | Feb 24, 2021 | — |
| 425 | Current report | Feb 9, 2021 | — |
| 425 | Current report | Jan 20, 2021 | — |
| 425 | Current report | Jan 12, 2021 | — |
| 425 | Current report | Dec 17, 2020 | — |
| 425 | Filing | Dec 14, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2020 | — |
| CORRESP | Letter to the SEC | Dec 7, 2020 | — |
| PRER14A | Filing | Dec 7, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2020 | — |
| D | Filing | Nov 22, 2017 | — |
| EFFECT | Filing | Nov 20, 2017 | — |
| CERTNAS | Auto-generated paper document | Nov 20, 2017 | — |
| 8-A12B | Filing | Nov 20, 2017 | — |
| CORRESP | Letter to the SEC | Nov 16, 2017 | — |
| CORRESP | Letter to the SEC | Nov 16, 2017 | — |
| CORRESP | Letter to the SEC | Nov 16, 2017 | — |
| CORRESP | Letter to the SEC | Nov 14, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 9, 2017 | — |
Showing 63 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719406
- Former names
- Big Rock Partners Acquisition Corp. (until May 24, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.